🟢 Biovie is trading 6% up — no confirmed catalyst

Biovie is trading at $1.41, up 6.02%, with no confirmed catalyst identified for the October 27 move.

• On October 26, BioVie announced it was invited to present bezisterim Long COVID trial data at an NIH-backed workshop on November 4–5; available reporting does not establish the announcement as the cause.
• The Nasdaq was up 0.68% and the S&P 500 was up 0.28%, so the provided market context offers no clear explanation.
• The prior session closed at $1.33, up 7.26%.